

*Outcomes of Patients with Endometrial
Cancer in Ain Shams University
Maternity Hospital*

Thesis

*Submitted for partial fulfillment of
Master degree in Obstetrics & Gynecology*

Presented by

Manar Mohamed Hegazy Abd El Rahman

M.B., B.Ch.2008

Supervised by

Prof.Dr.

Amr Hassan Fahmy El Shalakany

Professor of Obstetrics and Gynecology

Faculty of Medicine

Ain Shams University

Dr.

Ahmed El Sayed Hassan

Lecturer of Obstetrics and Gynecology

Faculty of Medicine

Ain Shams University

Faculty of Medicine

Ain Shams University

2014

Acknowledgement

I would like to express my deepest thanks and profound gratitude to **Prof.Amr Hassan Fahmy El Shalakany**, Professor of Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University for giving me the honor of working under his supervision, his continuous support and encouragement in every stage of this thesis.

I am also deeply grateful to **Dr. Ahmed El Sayed Hassan**, Lecturer of Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University for his help, support and his valuable scientific guidance.

List of contents

List of contents	Page
List of contents	I
List of abbreviations.	II
List of tables.	III
List of figures.	VI
Protocol : introduction, aim of the work and methods	VII
Review of literature:	1-45
Chapter 1: Anatomical, Histological and Pathological Overview	1
Chapter 2: Epidemiology and risk factors	11
Chapter 3: Diagnosis of Endometrial Carcinoma	21
Chapter 4: Management of Endometrial Cancer	29
Chapter 5: Uterine Sarcoma	40
Material and Methods.	46
Results.	51
Discussion.	73
Conclusion and recommendations.	82
Summary.	84
References.	86
Arabic summary.	1

Abbreviations

ACOG	American College of Obstetricians and Gynecologists
AEH	Atypical endometrial hyperplasia
AH	Abdominal hysterectomy
ASTEC	A Study in the Treatment of Endometrial Cancer
BT	Brachytherapy
CAH	Complex atypical hyperplasia
CH	Complex hyperplasia
EBRT	External beam radiotherapy
EEC	Endometrioid endometrial cancer
EEC	Endometrioid endometrial cancer
EIC	Endometrial intraepithelial carcinoma
FIGO	International Federation of Gynecology and Obstetrics
GOG	Gynecology oncology group
HCV	Hepatitis c virus
HLRCC	Hereditary leiomyomatosis and renal cell carcinoma
HNPCC	Hereditary nonpolyposis colorectal cancer
IHD	Ischemic heart disease
LCF	Liver cell failure
MRC	The Medical Research Council
NCCC	Comprehensive Cancer Center
NEEC	Non-endometrioid endometrial cancer
OS	Overall survival
PORTEC	Postoperative radiotherapy for endometrial cancer
RFS	Recurrence free survival
RT	Radiation therapy
SAH	Simple atypical hyperplasia
SEER	Surveillance, Epidemiology and End Results (SEER) national cancer database
SH	Simple hyperplasia
SIS	Saline infusion sonohysterography
TVS	Transvaginal ultrasound
VH	Vaginal hysterectomy
VHD	Ventricular heart disease
WHO	World Health Organization

List of tables

Number	Name	Page
Table (1)	The incidence of cancer for each histologic category of endometrial hyperplasia	3
Table (2)	Typical features of type I and type II endometrial cancers	4
Table (3)	Cellular classification of endometrial cancer	5
Table (4)	Staging of carcinoma of the corpus uteri	9
Table (5)	Risk factors for endometrial cancer	12
Table (6)	Response rates of selected single-agent cytotoxic chemotherapy in metastatic endometrial cancer without prior chemotherapy	34
Table (7)	Randomized trials of combination chemotherapy in metastatic endometrial cancer	35
Table (8)	GOG classification of uterine sarcomas	40
Table (9)	Distribution of studied cases according to personal data	51
Table (10)	Distribution of studied cases according Menopausal status, marital status and parity	53
Table (11)	Distribution of cases according to contraceptive method	54
Table (12)	Distribution of studied cases according to comorbid risk factors	55
Table (13)	Other associated morbidities	55
Table (14)	Distribution of cases according to BMI	56
Table(15)	Distribution of studied cases according Presenting symptom/ complaint	56
Table (16)	Distribution of cases according to method of obtaining	57

	pre-operative biopsy	
Table (17)	Distribution of cases according to stage	57
Table (18)	Distribution of cases according to pre and postoperative grade with mean age	58
Table (19)	Distribution of cases according to operations done	58
Table (20)	Distribution of cases according to the age and surgical stage	59
Table (21)	Distribution of cases according to postoperative histopathological type	60
Table(22)	Distribution of cases according to type of treatment	61
Table (23)	Distribution of cases according to stage and histopathological type	62
Table (24)	Distribution of cases according to stage and mod of treatment	63
Table (25)	Distribution of cases according patients follow up	63
Table (26)	Distribution of cases according to Duration of follow up in years	63
Table (27)	Distribution of cases according to outcome of follow up	63
Table (28)	Distribution of cases according to survival with cancer stage	64
Table(29)	Mean and median overall Survival time of studied cases in years	65
Table (30)	Survival time of studied cases according to mean and median overall survival time with stage	66
Table(31)	Overall survival of stage I in years	67
Table(32)	Overall survival of stage II in years	68
Table(33)	Overall survival of stage III years	69

Table (34)	Overall survival of stage IV in years	70
Table(35)	Overall survival of unstaged cases in years	71
Table(36)	Means and Medians for Survival Time for stump cancer	72
Table(37)	Five years survival in FIGO report 2006 in comparison with current study	72
Table(38)	Distribution of endometrial cancer according to stage in our study in comparison with different centers all over the world	76
Table (39)	Distribution of patients by stage and grade in surgically staged patients in FIGO report 2006 in comparison with current study	77
Table(40)	Distribution of endometrial cancer according to Histologic subtypes in FIGO report 2006versus current study	78
Table (41)	Mode of treatment in every stage in FIGO report 2006 in comparison with current study	79
Table(42)	Five years survival according to percent of cases in FIGO report 2006 in comparison with current study	81

List of Figures

Number	Name	Page
Figure(1)	Simple endometrial hyperplasia	3
Figure (2)	(a) Complex endometrial hyperplasia without atypia, (b) Complex with atypia	3
Figure(3)	Endometrioid carcinoma at low (A) and high power (B)	6
Figure (4)	Serous carcinoma at high power (A) showing a complex branching pattern. Clear cell carcinoma (B)	7
Figure (5)	Distribution of cases diagnosed with endometrial cancer by age group	52
Figure (6)	Mean and median overall Survival time of studied cases in years	65
Figure (7)	Survival time of studied cases according to mean and median overall survival time with stage	66
Figure(8)	Overall survival of stage I in years	67
Figure (9)	Overall survival of stage II in years	68
Figur (10)	Overall survival of stage III years	69
Figure(11)	Overall survival of stage IV in years	70
Figure (12)	Overall survival of unstaged cases in years	71
Figure (13)	Percent of cases diagnosed with endometrial cancer by age group in in our study in comparison with US	74
Figure (14)	Five years overall Survival in FIGO report 2006 in comparison with current study	80

Introduction

Endometrial cancer is the fourth most common cancer in women and the most common gynecologic malignancy, accounting for 6% of all female cancers. The American cancer society estimated 43,470 new cases and 7,950 deaths from endometrial cancer in 2010 (*Pant and Bristow, 2011*).

There appear to be two types of endometrial carcinoma: one, which is estrogen related, and one, which is not. Factors associated with estrogen-related endometrial carcinoma include: obesity, diabetes mellitus, hypertension, nulliparity, infertility, endogenous or exogenous estrogen, tamoxifen use and precursor lesions such as endometrial hyperplasia. These cancers are diagnosed early and have a good prognosis. Non estrogen-related endometrial carcinoma tends to be seen more often in older, non-obese, parous women and tends to be more aggressive (*Moffitt and Muderspach, 2010*).

Endometrial cancer can present as post-menopausal bleeding (PMB), persistent post-menopausal vaginal discharge due Pyometra or significant worsening in menstrual pattern or volume in pre-menopausal women. Presentation as a result of metastatic disease is uncommon and pain is generally not a feature. Most women (~90%) present with PMB. Approximately 10% of women with PMB will be diagnosed with endometrial cancer(*Holland, 2010*).

The recommended initial investigation is a trans-vaginal ultrasound scan for measurement of endometrial thickness and identification of ovarian masses. A thin endometrium (<5 mm) in the post-menopausal woman has a high negative predictive value for endometrial cancer and is reassuring(*Holland, 2010*).

A definitive diagnosis in PMB is made by histology. Historically endometrial samples have been obtained by dilatation and curettage. Nowadays it is more usual to obtain a sample by biopsy, which can be undertaken using samplers. All methods of sampling the endometrium will miss some cancers. Hysteroscopy and biopsy is the preferred diagnostic technique (*Symonds, 2003*).

The initial management of endometrial cancer was a total abdominal hysterectomy, bilateral salpingo oophorectomy and pelvic and para aortic node dissection. Post-surgical treatment was then based on features detected at the time of surgery (*Mutch, 2009*).

Postoperatively, all patients with deep myometrial invasion or a poorly differentiated cancer should have consideration for adjunctive therapy, which may include radiation, hormone therapy or chemotherapy (*Moffitt and Muderspach, 2010*).

Adjuvant Radiation can be delivered externally to the pelvis, as vaginal brachytherapy, or as a combination. Treatment can also be directed to the whole abdomen or to an extended field that includes the pelvis and para-aortic region. Indications for radiotherapy are generally in the adjuvant setting. The goal of adjuvant radiotherapy is to treat the pelvic lymph-node regions that might contain microscopic disease, as well as the central pelvic region including the upper vagina. Progestagens have been the cornerstone of hormonal treatment of metastatic endometrial cancer, and response is related to the presence of steroid hormone receptors(*Amant et al, 2005*).

Cytotoxic chemotherapy has no proven role in the management of early stage endometrial cancer but is used in patients with primary advanced or recurrent endometrial cancer. Many agents have been studied in the treatment of endometrial cancer, but few have shown significant single-agent activity. The most active single agents are doxorubicin and cisplatin, which give response rates of 20–40%(*Oehler et al, 2005*).

The overall prognosis for endometrial cancer is generally good and reflects early presentation of the disease in most cases. The 5-year survival rate for all stages is approximately 80% but varies with tumor grade and depth of myometrial invasion. Survival in stage I disease is 85-90% but then falls to approximately 70-75% for stage II, 45% for stage III and <30% for stage IV disease. Other factors that adversely affect prognosis include non-endometrioid histological sub-type and lymphovascular space invasion. Most endometrial cancer recurrences occur within the first 3 years after treatment. Follow-up is undertaken with the aim of detecting recurrence and identifying side-effects of treatment (*Holland, 2010*).

Aim of the Work

The aim of this study is to review patient's characteristics and to evaluate the survival estimates and treatment outcomes of patients with endometrial cancer managed at Gynecologic Oncology Unit, Ain Shams University in the period between Jan. 2000 and Dec. 2010.

Materials and methods

The study will be carried out at the Gynecologic Oncology Unit, Ain Shams University Maternity Hospital. It is a retrospective study that will include patients with endometrial cancer managed between Jan. 2000 and Dec.2010. The patient's case notes will be retrieved and the relevant data will be collected. Missing data will be completed by information obtained from the patients themselves or their relatives through phone calls or by post.

The data will include:

- ✧ Age.
- ✧ Residence.
- ✧ Occupation.
- ✧ Special habits if found.
- ✧ Phone number and/or postal address.
- ✧ Body mass index.
- ✧ Menstrual history:
 - Age at menarche.
 - Age at menopause.
- ✧ Marital status:
 - Married.
 - Not married.
 - Duration of marriage.
- ✧ Parity
- ✧ Contraceptive history:
 - Methods used.
 - Duration of use.
- ✧ Comorbid risk factors:

- Diabetes mellitus.
- Hypertension.
- Obesity.
- Chronic anovulatory states →PCO.
- Endometrial hyperplasia.
- Estrogen replacement without concomitant progesterone

↗ Past history of:

- Chronic medical problems
- Other malignancies

↗ Presenting symptom:

- | | |
|---------------------------|-------------|
| ▪ Bleeding | ▪ Discharge |
| ▪ Swelling | ▪ Pain |
| ▪ Accidentally discovered | ▪ others |

↗ Date and age of diagnosis.

↗ Investigation done and its results.

↗ Method of obtaining the preoperative endometrial biopsy

↗ Preoperative histological type and grade

↗ Surgical procedure.

↗ Lymphadenectomy: yes or no If yes,

- | | | |
|-----------------------------|-----------------------------|-----------|
| ▪ Pelvic lymphadenectomy | ▪ Preaortic lymphadenectomy | ▪ Or both |
| ▪ Number of nodes collected | | |

↗ Post-operative histological type and tumor grade

↗ Surgical stage

↗ Operative or postoperative complications

⇒ Adjuvant therapy:

⇒ Radiation therapy:

- Type ▪ Number of cycles
- Response ▪ Duration of therapy till completed

⇒ Chemotherapy:

- Type ▪ Number of cycles
- Response ▪ Duration of therapy till completed

⇒ Follow up data

⇒ Tumor recurrence

- Date and time to recurrence.
- Site of recurrence.
- Treatment of recurrence

⇒ Survival data:

- Overall survival
- Disease free survival

⇒ Date of death

⇒ Cause of death

- Cancer or treatment related.
- Non cancer related.